1 unknown, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 1, Withdrawn 1 |
Follow Sargramostim for Injection: new trials by email Literature Review of Sargramostim for Injection trials Research Report on Sargramostim for Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome Sargramostim for Injection, Saline Placebo - Down Syndrome | Phase 2 | Withdrawn | University of Colorado, Denver | 2023-10-23 | 2025-04-02 | |
| Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab UV1, Sargramostim for Injection, Pembrolizumab injection - Head and Neck Squamous Cell Carcinoma | Phase 2 | Unknown | Martin-Luther-Universität Halle-Wittenberg | 75 | 2021-08-02 | 2022-03-09 |
Down Syndrome (1) · Squamous Cell Carcinoma of Head and Neck (1)
Martin-Luther-Universität Halle-Wittenberg (1) · University of Colorado, Denver (1)
Germany (1) · United States (1)
Mascha Binder, MD (1) · Peter Pressman, MD (1)
PMID 33778150, PMID 35307513, PMID 38384801, PMID 40220758, PMID 40764401
R61AG074859 (1)